Evaluating LivQ-box® for diagnosing liver inflammation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the correlation between LivQ-box® parameters, measured by iLivTouch, and the severity of liver inflammation in patients diagnosed with nonalcoholic fatty liver disease (NAFLD). It involves a multi-center approach, analyzing data from 240 NAFLD patients, both retrospectively and prospectively. The study collects laboratory results, iLivTouch measurements, and liver biopsy findings to determine the diagnostic value of these parameters and establish cut-off values for different stages of liver inflammation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases;
* Age over 18 years old, gender not limited;
* Not combined with liver diseases (such as viral hepatitis, drug-induced liver injury, autoimmune liver disease);
* Perform iLivTouch examination within ± 14 days of liver pathology examination;
* No history of excessive alcohol consumption (converted to ethanol:\<140g/week for males,\<70g/week for females);

Where it's running

• Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Lai Wei
• Email: weilai@pkuph.edu.cn
• Phone: +86 13601281862

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Non-invasive blood and imaging tests for metabolic liver disease

  This project tests whether blood tests and imaging scans can diagnose and stage metabolic-associated steatohepatitis (MASH) and liver fibrosis in adults with metabolic risk factors.

  Recruiting at 4 sites Foundation for the National Institutes of Health · Miami, Florida and 3 other locations · NCT07122700

• Gepaktiv compared with UDCA and Ademetionine for MAFLD with enlarged liver

  This study will try the dietary supplement Gepaktiv to see if it improves liver enzymes, liver size, and fat in adults with MAFLD and hepatomegaly compared with UDCA and ademetionine.

  Recruiting Phenomen Pharma · Tyumen, Tyumen Oblast · NCT07068191

• Investigating how sugars affect fat accumulation in the liver

  This study tests how different types of sugars affect fat buildup in the liver of men, both non-obese and obese, to help understand better ways to manage liver health.

  Recruiting Institute for Clinical and Experimental Medicine · Prague, Czech Republic · NCT06751862

• Digoxin for NASH with stage 2–3 fibrosis

  This trial will see if taking once-daily digoxin helps clear NASH and reduce liver scarring in adults with biopsy-confirmed NASH and stage 2–3 fibrosis.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT06588699

• Impact of synbiotics on liver health and metabolism in fatty liver disease

  This study is testing whether taking synbiotics can improve liver health and metabolism in people with fatty liver disease.

  Recruiting Universitas Diponegoro · Semarang, Semarang · NCT06585982

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.